RxDoctor Payments Data

T'eria Mathews, NP

Family · Newport News, VANPI 1164885349

Payments from drug & device makers

$439in general payments, 2019–2025

Across 21 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shield Therapeutics Inc$70
  • Abbott$65
  • Novo Nordisk$59
  • AstraZeneca$46
  • Lilly USA, LLC$43
  • Amgen$36
  • plus $119 from 6 others

What the payments were for

  • Food & beverage$439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$439 in reported general payments places this provider in the 55th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$76,741
Medicare patients
197
Services billed
1,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$50,364
MounjaroTirzepatide26$27,306
JanuviaSitagliptin Phosphate27$26,590
EliquisApixaban30$25,541
XareltoRivaroxaban28$25,033
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$22,634
RybelsusSemaglutide15$21,845
TradjentaLinagliptin22$19,350
JardianceEmpagliflozin14$15,397
LinzessLinaclotide16$12,817
Dexlansoprazole DrDexlansoprazole28$3,878
Humalog Kwikpen U-100Insulin Lispro14$2,449
Lidocaine14$2,291
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,284
Atorvastatin Calcium204$2,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$59$72,20956 claims
Boehringer IngelheimTradjenta, Jardiance$24$34,74836 claims
Lilly USA, LLCMounjaro$43$27,30626 claims
PfizerEliquis$20$25,54130 claims
GSKTrelegy Ellipta$23$22,63416 claims
AbbVieLinzess$23$12,81716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,332 family providers in Virginia.

Other family in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →